ArticleArquivos de gastroenterologia2025
EXTRA-PANCREATIC MANIFESTATION IN AUTOIMMUNE PANCREATITIS VERSUS CONVENTIONAL PANCREATITIS: AN EGYPTIAN COHORT.
Article in Arquivos de gastroenterologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutoimmune pancreatitis (AIP) is a specific form of pancreatitis that is characterized by obstructive jaundice and sometimes associated with pancreatic masses, lymphoplasmacytic infiltrate and fibrosis, with a marked response to steroids. According to International Consensus Diagnostic Criteria AIP is categorized into type 1, type 2, and not otherwise specified (NOS). AIP-1 is one of the presentations of the IgG4-related disease (IgG4-RD) characterized by lymphoplasmacytic infiltration and more than ten IgG4-positive plasma cells per high-power field (HPF), storiform fibrosis, and obliterative phlebitis. Clinically, IgG4-RD is a systemic disease that can affect all organs. It can affect the bile ducts, kidneys, lymph nodes, prostate, and retroperitoneum.
objectiveRecognize patients with extra pancreatic manifestation in autoimmune pancreatitis as soon as possible to achieve optimal outcomes.
methodsA retrospective comparative study was conducted on the previously hospitalized patients to our main university hospital, during the period from June 2022 till June 2024. It is a retrospective study that was done through revision of the patient clinical, laboratory and imaging including CT/MRI of the abdomen and chest CT of all patients. 60 patients with pancreatitis were enrolled in the study. It was diagnosed based on at least two criteria of the following: (1) typical abdominal pain, (2) elevated amylase and/or lipase greater than 3 times, and (3) radiological findings match with pancreatitis. Cases were divided according to the International Consensus Diagnostic Criteria (ICDC) into group A: Autoimmune pancreatitis (AIP) defined by a specific form of pancreatitis characterized by obstructive jaundice with or without pancreatic masses, lymphoplasmacytic infiltrate and fibrosis (from laparotomy biopsies in suspected pancreatic cancer) and a marked response to steroids. And group B: conventional pancreatitis, with 30 patients in each group.
resultsA raised serum IgG4 was found in group A patients ranging from 135.0 mg/dL to 212.0 mg/dL with >95% specificity and sensitivity for AIP. The extra pancreatic associated diseases in AIP candidates, were detected in 23 patients (76.6%). Biliary tree complications were seen at 22 patients (73.3%), non calcular gall bladder disease was detected in 9 patients (30%), renal complications were found in 11 patients (36.6%), irrelevant lymphadenopathy in 10 patients (33.3%), retroperitoneal 3 patients (10%). In group B: there were biliary obstructive in 9 patients (30%), calcular cholecystitis was found in 19 patients (63%), with no other recorded extra pancreatic diseases. Chi square and Fisher Exact tests revealed significant differences between the two groups, as regards the extra pancreatic diseases in association with group A.
conclusionType 1 AIP has been associated with several extra pancreatic manifestations determining different clinical outcomes. Therefore, patient monitoring and a multisystem evaluation approach are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.